Grace Therapeutics (GRCE)

• Market cap: $51.2M
• 1 day: -1.49%
• 5 days: 2.8%
• 1 month: 9.24%
• 3 months: 5.08%
• 6 months: 13.36%
• Year to date: -17.25%
• 1 year: -15.13%
• 5 years: -72.42%
• 10 years: -95.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Employees: 6